We are live on ! Find out more
Arrowstreet Capital

Arrowstreet Capital Portfolio holdings

AUM $185B
1-Year Est. Return 39.58%
This Fund
S&P 500
This Quarter Est. Return
+10.23%
1 Year Est. Return
+39.58%
3 Year Est. Return
+145.48%
5 Year Est. Return
+192.07%
10 Year Est. Return
+749.68%
AUM
$43B
AUM Growth
+$121M
Cap. Flow
-$3.21B
Cap. Flow %
-7.47%
Top 10 Hldgs %
18.86%
Holding
2,029
New
505
Increased
717
Reduced
446
Closed
331

Top Buys

Rank Stock Value
1
INTC icon
Intel
INTC
+$285M
2
AMAT icon
Applied Materials
AMAT
+$234M
3
MU icon
Micron Technology
MU
+$185M
4
MRK icon
Merck
MRK
+$161M
5
NXPI icon
NXP Semiconductors
NXPI
+$152M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$505M
2
BAC icon
Bank of America
BAC
+$339M
3
NKE icon
Nike
NKE
+$335M
4
UNP icon
Union Pacific
UNP
+$329M
5
C icon
Citigroup
C
+$277M

Sector Composition

Rank Sector Weight
1 Technology 23.49%
2 Financials 16.82%
3 Consumer Discretionary 16.55%
4 Healthcare 14.39%
5 Industrials 8.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SDR
2026
DELISTED
SANDRIDGE MISSISSIPPIAN TRUST II
SDR
-99,594
Closed -$49K
AUO
2027
DELISTED
AU Optronics Corp
AUO
-65,600
Closed -$161K
STL
2028
DELISTED
Sterling Bancorp
STL
-185,300
Closed -$3.72M
SAFE
2029
DELISTED
Safehold Inc.
SAFE
-13,720
Closed -$418K

Similar funds

Arrowstreet Capital's Q4 2019 Portfolio in Review

As of Q4 2019, Arrowstreet Capital held 2,029 positions worth $43B, up 0.28% from $42.9B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Arrowstreet Capital withdrew a net $3.21B in Q4 2019, closing 331 positions and reducing 446 holdings. Its most notable exit was Celgene Corp, an estimated $505M position sold in full.

By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 19% a quarter earlier, followed by Financials and Consumer Discretionary.

Against the trend, Arrowstreet Capital opened a new position in Edwards Lifesciences worth $127M.

  • Arrowstreet Capital's largest Q4 2019 buy was Edwards Lifesciences: 1,637,208 shares worth $127M.
  • Arrowstreet Capital added most to Intel in Q4 2019, an estimated $285M increase.
  • Arrowstreet Capital's biggest Q4 2019 reduction was Union Pacific, cutting an estimated $329M.
  • Arrowstreet Capital fully exited Celgene Corp in Q4 2019, selling an estimated $505M.
  • Arrowstreet Capital's ten largest holdings make up 19% of its $43B portfolio in Q4 2019.
  • Arrowstreet Capital opened 505 new positions and closed 331 in Q4 2019.
  • Arrowstreet Capital's portfolio value rose 0.28% quarter-over-quarter to $43B.

Based on Arrowstreet Capital's 13F filing for Q4 2019, filed 13 Feb 2020.